Polo-like kinase 4 inhibition: a strategy for cancer therapy?
about
p53 protects against genome instability following centriole duplication failureLoss of KLF14 triggers centrosome amplification and tumorigenesis.A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.Binding of STIL to Plk4 activates kinase activity to promote centriole assemblyPLK4: a link between centriole biogenesis and cancer.Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma.
P2860
Polo-like kinase 4 inhibition: a strategy for cancer therapy?
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Polo-like kinase 4 inhibition: a strategy for cancer therapy?
@ast
Polo-like kinase 4 inhibition: a strategy for cancer therapy?
@en
Polo-like kinase 4 inhibition: a strategy for cancer therapy?
@nl
type
label
Polo-like kinase 4 inhibition: a strategy for cancer therapy?
@ast
Polo-like kinase 4 inhibition: a strategy for cancer therapy?
@en
Polo-like kinase 4 inhibition: a strategy for cancer therapy?
@nl
prefLabel
Polo-like kinase 4 inhibition: a strategy for cancer therapy?
@ast
Polo-like kinase 4 inhibition: a strategy for cancer therapy?
@en
Polo-like kinase 4 inhibition: a strategy for cancer therapy?
@nl
P2860
P1433
P1476
Polo-like kinase 4 inhibition: a strategy for cancer therapy?
@en
P2093
Andrew J Holland
P2860
P304
P356
10.1016/J.CCR.2014.07.017
P577
2014-08-01T00:00:00Z